Physician

Natalia Colocci, MD

According to 2025 Medicare claims, Natalia Colocci, MD (NPI: 1215948484) practices hematology/oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is SUTTER BAY MEDICAL FOUNDATION (NPI: 1013950807; TIN: 941156581) and primary practice location at 94301-2302. Colocci is affiliated with the Sutter Medicare Direct (ACO ID: A5279), participating under the MSSP model.

Colocci's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 500 traditional Medicare patients, billed 73,226 HCPCS/CPT codes, and received $1,604,023 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 799 prescription claims across 174 beneficiaries totaling $2,143,922 in drug costs, led by Xtandi (Enzalutamide). DME data shows 82 claims. Open Payments data shows 23 records totaling $9,362. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,260,436 and ending at $1,604,023. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $967,569 to $2,143,922. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	516	50,952	$1,260,436
2016	523	54,699	$1,231,791
2017	546	66,261	$1,422,891
2018	466	58,715	$1,204,375
2019	464	62,243	$1,143,998
2020	439	83,203	$1,466,672
2021	483	97,419	$1,753,532
2022	442	50,959	$937,402
2023	528	82,982	$1,661,520
2024	500	73,226	$1,604,023

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	139	758	$967,569
2016	126	739	$1,004,535
2017	155	810	$1,564,666
2018	136	796	$2,059,271
2019	144	850	$2,432,889
2020	152	886	$2,224,825
2021	160	878	$1,985,091
2022	164	729	$1,699,031
2023	208	879	$2,119,835
2024	174	799	$2,143,922

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	52	$24,131
2016	N/R	N/R	N/R
2017	N/R	97	$19,724
2018	N/R	70	$9,925
2019	N/R	N/R	N/R
2020	N/R	36	$2,743
2021	N/R	60	$3,767
2022	N/R	90	$2,890
2023	N/R	72	$9,269
2024	N/R	82	$2,035

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	141	368	$167
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	120	176	$116
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	126	189	$66
J3489	Injection, zoledronic acid, 1 mg	80	404	$5
J7050	Infusion, normal saline solution, 250 cc	90	107	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	43	1,290	$573,163
Erleada	Apalutamide	33	1,050	$485,111
Tukysa	Tucatinib	14	420	$342,006
Ibrance	Palbociclib	14	392	$242,035
Creon	Lipase/Protease/Amylase	13	380	$33,872

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	25	$800
J8700	Temozolomide, oral, 5 mg	N	N/R	15	$527
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$389
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$320

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$262	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	18	$9,100	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Natalia Colocci, MD?

Tedicare shows public-source Medicare data for Natalia Colocci, MD (NPI 1215948484), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Natalia Colocci, MD have ACO affiliation data?

Natalia Colocci, MD is shown with ACO affiliation data for Sutter Medicare Direct (MSSP, ACO ID A5279).

What billing organization is linked to Natalia Colocci, MD?

Natalia Colocci, MD is linked to SUTTER BAY MEDICAL FOUNDATION (billing NPI 1013950807) in the available physician profile data.

Does Natalia Colocci, MD have Open Payments data?

Natalia Colocci, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.